Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454688 · ClinicalTrials.gov registry record · Phase 2
Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
A Phase 2 study, sponsored by Tioga Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 596
- Enrollment target
NCT00454688: Completed Phase 2 study, sponsored by Tioga Pharmaceuticals.
NCT00454688 is a Phase 2 study that has completed, run by Tioga Pharmaceuticals. The registered enrollment target is 596 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (348% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00454688, a Phase 2 study, has completed, sponsored by Tioga Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 596 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome.
Primary Outcome
The primary efficacy endpoint of the study was the total number of months with adequate relief of IBS pain or discomfort.
Interventions
- DRUG Placebo
- DRUG Asimadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00454688 record still lists
NCT00454688 is an interventional study that assigns participants to a tested intervention. The registered 596 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (348% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00454688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00454688 about?
NCT00454688 is a clinical study titled "Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome". The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome.
What is the current status of trial NCT00454688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 596 participants. The study started on 2006-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00454688?
The interventions under investigation include: Placebo (DRUG), Asimadoline (DRUG).
Who is sponsoring clinical trial NCT00454688?
This trial is sponsored by Tioga Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00454688's enrollment target sits among peer trials
596 56th of 2000 higher than 1,944 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT05723198 · 595 participants · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia